![]() |
Pradaxa® vs Warfarin...
November 1, 2014 - Featured , In the News / Politics By: Kevin Lin, PharmD Candidate c/o 2015 — The FDA recently completed an observational cohort study that compared Pradaxa® (dabigatran) to warfarin for rates of ischemic stroke, intracranial hemorrhage, major gastrointestinal bleed, myocardial infarction, and death. The study enrolled more than 134,000 patients, with 64% over the age of 65 and found a lower risk… |
![]() |
In Wine There Is Truth...
October 1, 2014 - Featured , In the News / Politics By: Katharine Cimmino, Editor-in-Chief – Many articles and quick one-line stories have been cropping up on the internet boasting the benefits of drinking wine regularly. While headlines such as, “Drinking a Glass of Red Wine is the same as Getting an Hour of Exercise, Says New Study,” may make readers ecstatic that their drinking habits… |
![]() |
Reservoir of Migraine Therapies Includes Analgesics, AE...
September 1, 2014 - Clinical , Featured By Davidta Brown, Senior Staff Editor – The pain, nausea, and light or sound sensitivity that comprise a migraine attack afflict more than 10% of individuals around the world, easily making migraines one of the most globally debilitating diseases of the present day.1 According to the International Headache Society (IHS), migraines are defined by both… |
![]() |
Quantifying the Benefits of Pharmacist Prescribing Powe...
July 1, 2014 - Featured , Professional Advice / Opinions By Davidta Brown, Senior Staff Editor – The idea of granting pharmacists the right to prescribe, as well as to counsel and dispense, has long been a source of controversy among healthcare professionals. A study out of the University of Alberta in Canada, published online in mid-April, provided some much needed concrete data for an… |
![]() |
Antipsychotic Use in the Elderly with Dementia...
July 1, 2014 - Clinical , Featured By: Ada Seldin, Staff Editor – The overuse of antipsychotics in the nursing home population for off-label indications continues to impact patient safety. In 2005, the FDA issued a black box warning that stated, “The treatment of behavioral disorders in elderly patients with dementia with atypical antipsychotic medications is associated with increased mortality.” The evidence… |
![]() |
New Considerations for Testosterone Therapy...
June 1, 2014 - Featured , In the News / Politics By: Jenny Park PharmD Candidate c/o 2015 – Testosterone is a hormone essential to male development. However, treatment of testosterone deficiency is FDA approved only when accompanied with another medical condition such as failure of testicles to produce testosterone due to chemotherapy or even genetic conditions.1 In 2011, 5.3 million prescriptions for testosterone were written… |
![]() |
The Surgeon General’s 2014 Report on Smoking...
April 1, 2014 - Featured , In the News / Politics By: Ada Seldin, Staff Editor – Since the first release of the Surgeon General’s Report on smoking 50 years ago, it has become clear that smoking results in premature death and a myriad of diseases, affecting almost every organ system. Public health initiatives to increase awareness, prevent initiation, and promote smoking cessation have been marginally… |
![]() |
A Brave New World for Lipid Management...
March 1, 2014 - Featured , In the News / Politics By: Amrita Singh, PharmD Candidate c/o 2015 – Last November, the American College of Cardiology and the American Heart Association released new lipid guidelines, which will transform the way we manage our patients with hyperlipidemia. Earlier, lipid management was based on the ATP-III guidelines, which emphasized the use of several lipid-lowering medications to reach target… |
![]() |
Ponatinib Taken Off the Market...
December 1, 2013 - In the News / Politics By: Sherine Jaison, PharmD Candidate c/o 2015 – The leukemia chemotherapy drug ponatinib (Iclusig) has just been taken off the market. The drug was under investigation by the Food and Drug Administration (FDA) following several reports of serious and life threatening blood clots and narrowing of the blood vessels.1 Ponatinib is a BCR-ABL tyrosine kinase… |
![]() |
Zecuity(TM): Novel Treatment Option for Migraines...
November 1, 2013 - Clinical By: Arya Mathew, PharmD Candidate c/o 2014 – About twelve percent of the U.S. population suffers from migraines, affecting adult women three times more than adult men. Migraines are returning attacks of moderate to severe, throbbing or pulsing pain, usually on one side of the head. Along with the severe pain, migraine sufferers also experience… |
![]() |
Canagliflozin (Invokana®): New Type 2 Diabetes Drug...
October 1, 2013 - Clinical By: Sang Hyo Kim, Staff Editor – On March 29th 2013, the U.S Food and Drug Administration approved canagliflozin (Invokana®), a new form of a diabetic drug for patients with type 2 diabetes mellitus.1 Canagliflozin is in a new class of medications called sodium glucose co-transporter 2 (SGLT2) inhibitors and is the only oral, once-daily… |
![]() |
Nattokinase use in DVT prophylaxis...
October 1, 2013 - Clinical Samad Tirmizi, Pharm. D. Candidate c/o 2014 – Deep vein thrombosis (DVT) is a clot formation that occurs within deep veins, generally in the legs. This can cause swelling and pain due to the engorged vessels, and can eventually result in further complications such as a pulmonary embolism. Patients at high risk for DVT are… |
![]() |
New Findings Regarding Cardiovascular Adverse Events wi...
August 1, 2013 - Clinical , Featured By: Aleena Cherian, Co-Copy Editor [Graphics-Focused] – Attention deficit/hyperactivity disorder (ADHD) is a chronic neurological behavior characterized by persistent patterns of inattention and/or hyperactive behavior, resulting in a wide range of emotional, functional, and neurocognitive impairments.1,2 First line therapy for ADHD consists of stimulant medications together with non-pharmacologic interventions, and has been shown to improve… |
![]() |
Comparison of the New Oral Antithrombotics and Warfarin...
August 1, 2013 - Clinical , Featured By Omar Khalid Pharm.D. Candidate c/o 2014 – The outpour of a multitude of new oral anticoagulants in recent years has health care professionals questioning whether they should switch the patients over, and what new agents should be used. With the recent addition of dabigatran (Pradaxa®) in October 2010, rivaroxaban (Xarelto®) in November 2011, and… |
![]() |
Two New Agents for the Treatment of Obesity...
August 1, 2013 - Clinical , Featured By: Nathan Trustman, PharmD Candidate c/o 2013, AMSCOP at LIU – Obesity is defined as having a body mass index (BMI) of 30 kg/m2 or greater. It is thought to be the result of an imbalance between energy intake and energy expenditure, possibly due to a number of genetic and environmental factors.1 It is estimated… |
![]() |
Solving the HCV Enigma: Current and Future Drug Therapy...
July 1, 2013 - Clinical , Featured By: Tamara Yunusova, Senior Staff Editor – Approximately 3.2 million Americans have chronic hepatitis C infection.1 While acute cases are not common, rates of chronic hepatitis C continue to surge due to the recent discovery of the virus in 1989 and consequently, the establishment of a test screening for HCV antibodies in 1992.1 HCV has… |
![]() |
Calcium Intake and Risk of Myocardial Infarction...
February 1, 2013 - Clinical , Featured By: Lila Ahmed, PharmD Candidate c/o 2013 – In the past, numerous research efforts have attempted to prove the benefits and risks of calcium and multivitamin supplements with little success. Most of the studies performed were inconclusive and did not provide us with significant data; while some studies have found that calcium is beneficial for… |
![]() |
FDA Approves Apixaban For Nonvalvular Atrial Fibrillati...
January 1, 2013 - Clinical , Featured , In the News / Politics By: Alexandra Alleva, PharmD candidate c/o 2013 – As of December 28th, Bristol-Myers Squibb and Pfizer’s brand name oral anticoagulant, Eliquis® (apixaban), attained FDA approval.1 This occurred one month after its approval in Europe and Canada, following longer than expected waits in the US due to further investigation requests by the FDA.2 The much-anticipated anticoagulant is… |
![]() |
Antiplatelet Use Following Acute Coronary Syndromes...
September 1, 2012 - Clinical , Featured By: Addolorata Ciccone, Co-Copy Editor – Acute Coronary Syndromes Acute coronary syndrome (ACS) is a myocardial ischemia caused by obstruction of coronary arteries. ACS is stratified into three types, based on electrocardiogram (EKG) changes and the presence of cardiac biomarkers (e.g. troponin, creatinine phosphokinase, and myoglobin). To guide treatment plans, it is important to identify… |
![]() |
Lipid Panels: Fasting or Non-Fasting?...
April 1, 2012 - Clinical By: Nagma Gargi, Pharm D. Candidate 2013 – Traditionally, lipid panels are drawn under fasting conditions. Is there data supporting decreased accuracy in a non-fasting lipid panel? Cholesterol is an essential tool for our body for the synthesis of hormones, vitamin D, and bile acids. However, an excess of cholesterol pose a serious threat to… |
![]() |
Brilinta® vs. Plavix® in Patients with Acute Coronary...
February 1, 2012 - Clinical , Featured By: Ronik Saha, Pharm.D. Candidate c/o 2013 – Clopidogrel (Plavix®) is a thienopyridine antiplatelet agent, which exerts its antiplatelet effects via in vivo conversion to an active thiol metabolite that irreversibly blocks the P2Y-12 component of platelet ADP receptors. This prevents activation of the GP2B/3A complex, thereby preventing platelet aggregation. Along with aspirin, clopidogrel reduces… |
![]() |
New Oral Direct Thrombin Inhibitors and Factor Xa Antic...
January 1, 2012 - Clinical , Featured , In the News / Politics By: Neal Shah – Anticlotting agents are staples in the prevention and treatment of thrombotic disorders, such as deep vein thrombosis, stroke, pulmonary embolism, myocardial infarction, and atrial fibrillation.1 Intravenous medications, such as unfractionated heparin (UFH), low molecular weight heparin (LMWH), and direct thrombin inhibitors (DTI), are commonly used in, both, inpatient and outpatient settings.… |
![]() |
FDA Approves Edarbyclor®...
January 1, 2012 - Clinical , In the News / Politics By: Gokul Kalla, Pharm.D. Candidate c/o 2013 – Hypertension is a chronic disease that affects one out of every three Americans. Leaving the condition untreated could increase the risk of serious health consequences such as a stroke or a heart attack. On December 21, the FDA approved Takeda Pharmaceuticals’ Edarbyclor® (azilsartan medoxomil and chlorthalidone) for… |
![]() |
Clevidipine in the Management of Hypertensive Emergency...
January 1, 2012 - Clinical , Featured By: Neal Shah – Defined by the Joint National Committee, hypertension (HTN) is a systolic blood pressure (SBP) greater than or equal to 140 mmHg and a diastolic blood pressure (DBP) greater than or equal to 90 mmHg. Patients with Stage 1 HTN have a SBP between 140 and 159 mmHg and DBP between 90… |
![]() |
Clinical Update: Heart Failure and Osteoporosis-Related...
October 1, 2011 - Clinical , Featured By: Mahdieh Danesh Yazdi – Heart failure is a condition in which the heart cannot pump blood efficiently to adequately perfuse tissues. It is often associated with serious consequences, such as kidney failure, liver dam-age, heart attack, and stroke. Patient care is focused on preventing these complications. Recently, attention has turned to other concerns: studies… |